Front matter (notice n° 1573192)

détails MARC
000 -LEADER
fixed length control field 02198cam a2200193 4500500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20251214025921.0
041 ## - LANGUAGE CODE
Language code of text/sound track or separate title fre
042 ## - AUTHENTICATION CODE
Authentication code dc
100 10 - MAIN ENTRY--PERSONAL NAME
Personal name Peaucelle, Anne-Sophie
Relator term author
245 00 - TITLE STATEMENT
Title Front matter
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Date of publication, distribution, etc. 2025.<br/>
500 ## - GENERAL NOTE
General note 14
520 ## - SUMMARY, ETC.
Summary, etc. In recent months, we have been witnessing a revolution in the field of inflammatory bowel disease (IBD). The rapid expansion of our therapeutic arsenal—as evidenced by the recent arrival on the market of Janus kinase inhibitors (JAKis), anti-IL23 agents, and sphingosine 1-phosphate modulators, along with their reimbursement in France—offers genuine promise for the management of our patients.This revolution is unfolding alongside a major global epidemic of Crohn’s disease and ulcerative colitis. For a long time, these conditions were regarded as “diseases of the young.” However, the global increase in incident IBD cases has revealed a growing number of presentations with either pediatric-onset or, conversely, geriatric-onset forms, each carrying their own medical, social, and environmental specificities.At a time when we are broadening our treatment perspectives and setting increasingly ambitious therapeutic goals, we often find that these “medical” objectives clash with those of our patients. Management must therefore be adjusted to take into account not only the patient’s profile (age, mobility, schooling, comorbidities, life projects, etc.) but also the characteristics of our therapies (e.g., safety, tolerance, administration mode, possibility for reimbursement). All these factors represent a real challenge for the practitioner and make the management of IBD patients increasingly complex. Here, we offer an overview of the latest news in IBD, addressing the various themes necessary to ensure a holistic approach to patient care.
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Barrau, Mathilde
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Bastide, Laetitia
Relator term author
700 10 - ADDED ENTRY--PERSONAL NAME
Personal name Roblin, Xavier
Relator term author
786 0# - DATA SOURCE ENTRY
Note Revue internationale de soins palliatifs | 39 | 3 | 2025-09-01 | p. 110-110 | 1664-1531
856 41 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://stm.cairn.info/journal-revue-internationale-de-soins-palliatifs-2025-3-page-110?lang=en&redirect-ssocas=7080">https://stm.cairn.info/journal-revue-internationale-de-soins-palliatifs-2025-3-page-110?lang=en&redirect-ssocas=7080</a>

Pas d'exemplaire disponible.

PLUDOC

PLUDOC est la plateforme unique et centralisée de gestion des bibliothèques physiques et numériques de Guinée administré par le CEDUST. Elle est la plus grande base de données de ressources documentaires pour les Étudiants, Enseignants chercheurs et Chercheurs de Guinée.

Adresse

627 919 101/664 919 101

25 boulevard du commerce
Kaloum, Conakry, Guinée

Réseaux sociaux

Powered by Netsen Group @ 2025